Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H27N5O2 |
Molecular Weight | 429.5142 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(C(NCC2CCN(CC2)C(=O)C=C)=NC=N1)C3=CC=C(OC4=CC=CC=C4)C=C3
InChI
InChIKey=QUIWHXQETADMGN-UHFFFAOYSA-N
InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
Evobrutinib is a highly selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). It potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of B cells and innate immune cells such as monocytes and basophils. Evobrutinib demonstrated effectivity in autoimmune disease preclinical models. Evobrutinib is being developed by Merck Serono for the treatment of various autoimmune disorders.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/31075187
double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C124801
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZA45457L1K
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
1415823-73-2
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
DB15170
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
100000174630
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
71479709
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
C141427
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
10394
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY | |||
|
KL-175
Created by
admin on Sat Dec 16 17:40:40 GMT 2023 , Edited by admin on Sat Dec 16 17:40:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY